Categories Technology

Coupa Software Q2 earnings: What’s on the cards

Coupa Software (NASDAQ: COUP), a technology firm with a focus on Business Spend Management, is slated to report second-quarter 2020 financial results after the closing bell on Tuesday, September 3.

Wall Street expects to see continued growth in top-line, helped by the strength in subscriber revenues. Analysts expect the San Mateo, California-based firm to report a 38.5% increase in revenues to $85.38 million.

The analysts’ expectation falls within the management projection range of Q2 revenues between $84.5 million and $85.5 million. The management had also projected subscription revenues in the range of $77-78 million.

READ: Nutanix beats the market in Q4, stock jumps

For the second quarter, the management expects an adjusted loss of 10-12 cents per share. The street estimate is pegged at the lower end of this projection range at 10 cents per share loss. In three of the past four quarters, the software company had surpassed Wall Street projections on the bottom-line, while it was in line with the estimate once.

Coupa had recently forged partnerships with PayPal (NASDAQ: PYPL) and Citigroup (NYSE: C) with a focus on making business payments more efficient. The company had also last month acquired contract lifecycle management solutions firm Exari to integrate into its BSM platform. Look out for any updates on how these alliances are working out financially for the firm.

READ: Hewlett Packard Enterprise beats Q3 EPS by 5 cents

Coupa had an exceptionally good year so far, with its stock soaring 126% in the year-to-date period. During the same period, the iShares Expanded Tech-Software ETF has gained just 24%.

Coupa is currently trading near its 12-month price target, so a post-earnings rally may be unlikely.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top